Streetbeat News

Partnerships

ATAI

ATAI Life Sciences has made a strategic investment in Beckley Psytech to expedite the clinical development of short-duration psychedelics. This move aims to advance treatments in the mental health space, leveraging Beckley Psytech's focus on 5-MeO-DMT and other compounds for various psychiatric and neurological conditions.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:23 pm

CMND

SPRC

SciSparc and Clearmind Medicine have successfully collaborated throughout 2023 and are planning to enhance a variety of psychedelic-based treatments. Their joint efforts aim to innovate and improve therapeutic options in the field of psychedelic medicine.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:21 pm

OSUR

OraSure Technologies has taken the lead in the Series B financing round and has established extensive strategic distribution agreements with Sapphiros and its related entities. This move could potentially expand OraSure's market reach and strengthen its distribution capabilities.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:17 pm

RPID

Rapid Micro Biosystems has announced that Samsung Biologics has chosen its Growth Direct platform for automating microbial quality control processes. This selection could streamline Samsung Biologics' QC operations, potentially improving efficiency and reliability in their production facilities.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:13 pm

BIIB

DNA

Ginkgo Bioworks has successfully completed a collaboration with Biogen, aimed at enhancing the productivity of Biogen's gene therapy manufacturing platform. This collaboration could potentially lead to more efficient production processes for gene therapies.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:11 pm

EVO

Shares of Evotec SE (EVO) are down in premarket trading after the announcement that CEO Werner Lanthaler is stepping down for personal reasons. Despite this, Evotec confirmed its 2023 revenue guidance of €750-790 million. Additionally, Evotec has entered into an AI-powered multi-target collaboration with Owkin, focusing on oncology, immunology, and inflammation. This partnership will leverage Owkin's AI for target discovery and Evotec's R&D platform, with Evotec receiving R&D funding, potential milestone payments, and royalties from Owkin.

Portfolio Pulse from Nabaparna Bhattacharya

January 04, 2024 | 12:11 pm

LE

Lands' End has launched an exclusive women's swimwear collection featuring nearly 70 pieces, which will be available for purchase at Target stores.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:55 am

GIB

CGI, also known as GIB on the NYSE, has been chosen by NATS, the UK's air traffic control service, to assist in transforming its digital infrastructure. This partnership aims to modernize the technological framework that supports air traffic management in the UK.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:32 am

FSLR

First Solar, Inc. has signed a 15-year Power Purchase Agreement (PPA) with Cleantech Solar, a leading provider of renewable energy solutions in India and Southeast Asia. This agreement will enable First Solar to supply solar power to Cleantech Solar's customers in the region, reinforcing First Solar's presence and commitment to the renewable energy market in Asia.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 11:04 am

TNGX

Medivir AB announced that its licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor for treating various HRD+ cancers. The FDA cleared the Investigational New Drug application for TNG348 in September 2023. TNG348 targets up to 50% of ovarian, 25% of breast, 10% of prostate, and 5% of pancreatic cancers with HRD+ including BRCA1/2 mutations. Tango is developing TNG348 based on a preclinical USP1 program licensed from Medivir in 2020.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 7:59 am